Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 25Neoplasms 9Kidney Neoplasms 8Prostatic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Colorectal Neoplasms 4Carcinoma, Medullary 4Carcinoma 4Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Pain 2Ovarian Neoplasms 2Liver Neoplasms 2von Hippel-Lindau Disease 1Urologic Neoplasms 1Thyroid cancer, follicular 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1Kidney Diseases 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × cabozantinib × Clear all
NCT03634540 2024-12-20

MK-6482-003

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Active not recruiting
118 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡